Document is current
Any future updates will be listed below
-
Authors
Tsuji, Takayuki
Matsuda, Satoru
Sato, Yuta
Tanaka, Koji
Sasaki, Ken
Watanabe, Masaya
Hamai, Yoichi
Nasu, Motomi
Saze, Zenichiro
Nakashima, Yuichiro
Nomura, Motoo
Yamamoto, Shun
Booka, Eisuke
Ishiyama, Koshiro
Bamba, Takeo
Sakanaka, Katsuyuki
Tsushima, Takahiro
Takeuchi, Hiroya
Kato, Ken
Kawakubo, Hirofumi
- License Information
-
More Information
Article History
Received: 20 May 2024
Accepted: 29 August 2024
First Online: 12 September 2024
Disclosure
: Motoo Nomura has received honoraria from ONO, BMS, and MSD, and advisory board fees from ONO. Shun Yamamoto has received honoraria from ONO, BMS, MSD, and Taiho; advisory board fees from ONO; and expert testimony fees from Hokuto. Katsuyuki Sakanaka has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Novartis Pharma, and support for attending meetings and/or travel from MSD. Ken Kato reports funding, paid to the institution, from MSD, Ono Pharmaceuticals, BMS, Beigene, Shionogi, Merck Biopharma, Oncolys BioPharma, Daiichi Sankyo, Novartis, Taiho Pharmaceutical, Janssen, AstraZeneca, and Chugai. Takayuki Tsuji, Satoru Matsuda, Yuta Sato, Koji Tanaka, Ken Sasaki, Masaya Watanabe, Yoichi Hamai, Motomi Nasu, Zenichiro Saze, Yuichiro Nakashima, Eisuke Booka, Koshiro Ishiyama, Takeo Bamba, Takahiro Tsushima, Hiroya Takeuchi, and Hirofumi Kawakubo have no conflicts of interest to declare that may be relevant to the contents of this study.
